Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research note released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their price objective on Trevena from $225.00 to $125.00 and set a buy rating on the stock in a research note on Thursday, May 16th.

Trevena Price Performance

Shares of NASDAQ TRVN opened at $4.13 on Thursday. The company has a 50-day moving average price of $4.94 and a 200-day moving average price of $8.79. The stock has a market capitalization of $3.51 million, a P/E ratio of -1.54 and a beta of 1.03. Trevena has a 1 year low of $3.35 and a 1 year high of $28.00.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($9.25) by $9.02. The company had revenue of $0.33 million for the quarter. As a group, equities research analysts anticipate that Trevena will post -32.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC bought a new stake in shares of Trevena, Inc. (NASDAQ:TRVN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena at the end of the most recent reporting period. Institutional investors and hedge funds own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.